An excellent international resource for the laboratory equipment industry.
A new class of drugs reduced the risk of patients contracting a serious and often deadly side effect of lifesaving bone marrow transplant treatments, according to a study from researchers at the Univ. of Michigan Comprehensive Cancer Center.
The study, the first to test this treatment in people, combined the drug vorinostat with standard medications given after transplant, resulting in 21 percent of patients developing graft-vs.-host disease compared to 42 percent of patients who typically develop this condition with standard medications alone.
Read more: http://www.laboratoryequipment.com/news/2012/12/drug-cuts-deadly-transplant-risk-half